Noticias y Actividades de 5AM Ventures
Ejecutivos
Ver el organigrama con sus 24 ejecutivos principales
Biografías más buscadas en 5AM Ventures
- Andrew Schwab, Founder and Co-Managing Partner
- Kush Parmar, Co-Managing Partner
- John Diekman, Founding Partner
Recientes movimientos de ejecutivos en 5AM Ventures
- Lauren Daniel que ha sido Chief Compliance Officer and Deputy General Counsel, ha ascendido a General Counsel and Chief Compliance Officer (noticia publicada el 5 de marzo de 2026).
- Paula Soteropoulos, Venture Partner, ha dejado la empresa (noticia publicada el 24 de febrero de 2026).
- Zoë Rubin, se ha incorporado a la empresa como Director of Compliance (noticia publicada el 24 de febrero de 2026).
Haga clic aquí para ver otros movimientos en 5AM Ventures
Crear su alerta
para seguir los movimientos de los ejecutivos en 5AM Ventures.
Fondo
5AM Ventures tiene 1.642 competidores entre los que se incluyen Griffin Gaming Partners (Estados Unidos), BlackRock (Estados Unidos) y KKR (Estados Unidos).
Popular M&A news in Fondo
- DigitalBridge Group has announced the acquisition of ArcLight Capital Partners (publicado el 3 de junio de 2026).
- Prime Capital Financial ha Access Capital Partners adquirido (publicado el 2 de junio de 2026).
- Frazier Healthcare Partners ha Altruix adquirido (publicado el 29 de mayo de 2026).
Otros contactos sugeridos en el sector Fondo
Noticias
Últimos comunicados de prensa de 5AM Ventures
- NodThera Announces Late-Breaking Oral Presentation at the 94th EAS Congress - Nodthera
- Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026
- Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
- Entrada Therapeutics | Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study
- News – Page 130 – 5AM Ventures
- Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer | Arvinas
- CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation • Tue, 04/28/2026 - 08:00
- Precede Biosciences Launches Precede Bio Insight™, a Genome-Wide Liquid Biopsy for Functional Tumor Biology at AACR 2026 | Precede Biosciences New
- Entrada Therapeutics | Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
- Fellow Health Appoints Industry Executive Paul Kappelman as Independent Chairman of the Board
- View more press releases Close
Redes sociales sobre 5AM Ventures
- 5AM Ventures en Wikipedia, Google News y Yahoo Finance
- 5AM Ventures en LinkedIn, Twitter y YouTube
